Boston Scientific Corporation (BSX)
NYSE: BSXHealthcareMedical DevicesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 41.64 +0.14%
BSX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $60.26B
- P/E (TTM)
- 16.83
- Forward P/E
- 12.29
- EPS (TTM)
- $2.47
- Dividend yield
- None
- 52-week range
- 41.50 – 105.65
- Day range
- 41.50 – 42.51
- Volume / Avg
- 15.78M / 19.67M
- Beta
- —
- Shares outstanding
- 1.45B
- Next earnings
- Oct 28, 2026
52-week range
BSX stock today
Shares of Boston Scientific (BSX) finished lower on Oct 7 at $41.58, a drop of 1.45% or $0.61 per share, versus the S&P 500's 0.22% decline. Shares are 60.6% below their 52-week high of $105.65, set on Nov 13, 2025 and 0.2% above the 52-week low of $41.50, near the bottom of the past year's range. BSX is down 56.0% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 56.3%.
At 16.8x trailing earnings, Boston Scientific trades below the peer-group median of 23.6x. Its forward P/E of 12.3x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. The company is scheduled to report Sep/2026 results on Oct 28 before the market opens; analysts expect EPS of $0.76.
Summary generated from market data by MetaCap's automated system. Methodology
About Boston Scientific
Company profileBoston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems.
- Sector
- Healthcare
- Industry
- Medical Devices
- CEO
- Mr. Michael F. Mahoney
- Headquarters
- Marlborough, MA
- Employees
- 59,000
- Website
- bostonscientific.com
Financial highlights
Full financialsIn fiscal 2025, Boston Scientific generated $20.07 billion in revenue, up 19.9% from fiscal 2024, its 5th consecutive year of revenue growth. Net income was $2.89 billion (+56.7% year over year), for a net margin of 14.4% versus a median of 8.8% in the prior 5 years. Gross margin was 69.0% (up from 68.6%) and operating margin 18.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $20.07B | $16.75B | $14.24B | $12.68B | $11.89B |
| Growth | +19.87% | +17.61% | +12.29% | +6.68% | +19.92% |
| Net income | $2.89B | $1.85B | $1.59B | $698.00M | $1.04B |
| EPS (diluted) | $1.94 | $1.25 | $1.07 | $0.45 | $0.69 |
Analyst forecast
ForecastConsensus (31 analysts)
buy
Avg. price target
$59.90+44.06%
- Strong buy 7
- Buy 18
- Hold 6
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 28, 2026
- EPS estimate
- $0.76
- Last reported (Q2 2026)
- Aug 3, 2026
- EPS actual vs est.
- $0.61 vs —
BSX news
All BSX news- Can J&J's MedTech Business Rebound in Q3 After Q2 Slowdown?NasdaqJNJ, BSX, MDT, SYK
- FedEx Takes Over #181 Spot From Boston ScientificNasdaqFDX, BSX
- Friday's ETF with Unusual Volume: HTECNasdaqHTEC, BSX, MRNA, QGEN
- Can ISRG Offset China Weakness With Expansion in India and Japan?NasdaqISRG, BSX, MDT
- Boston Scientific's MedSurg Diversification Bolsters Growth ProspectsNasdaqBSX, MDT, TFX
- Boston Scientific Leans on Acquisitions to Drive Long-Term GrowthNasdaqBSX, MDT, SYK
- Boston Scientific's ICVT Business Gains Momentum: Can Growth Continue?NasdaqBSX, MDT, SYK
Boston Scientific peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| EWEdwards Lifesciences Corporation | 85.78 | -0.81% | $49.44B | vs BSX |
| DXCMDexCom Inc. | 84.30 | +1.09% | $31.81B | vs BSX |
| GEHCGE HealthCare Technologies Inc. | 64.67 | -0.15% | $29.21B | vs BSX |
| PHGKoninklijke Philips N.V. NY Registry Shares | 24.09 | -0.25% | $23.55B | vs BSX |
| STESTERIS plc (Ireland) | 209.68 | +0.49% | $20.44B | vs BSX |
| ZBHZimmer Biomet Holdings Inc. | 88.49 | -1.33% | $16.88B | vs BSX |
| SYKStryker Corporation | 275.40 | -1.01% | $105.64B | vs BSX |
| MDTMedtronic plc. | 85.51 | -1.81% | $109.38B | vs BSX |
Indexes, lists and sector
Index membership
Appears in lists
Boston Scientific stock FAQ
What is Boston Scientific's stock price today?
BSX last traded at $41.58 as of Oct 7, 4:00 PM EDT, down 1.45% on the day. Prices are delayed at least 15 minutes.
Does Boston Scientific pay a dividend?
No. Boston Scientific does not currently pay a regular cash dividend.
When is Boston Scientific's next earnings date?
Boston Scientific is expected to report earnings on Wednesday, October 28, 2026. Analysts expect EPS of $0.76.
What is BSX's P/E ratio?
BSX trades at a trailing P/E ratio of 16.83 and a forward P/E of 12.29, compared with a median of 23.6 for its closest peers.
Is Boston Scientific in the S&P 500?
Yes. Boston Scientific (BSX) is a constituent of the S&P 500 index.
Who is Boston Scientific's CEO?
Mr. Michael F. Mahoney is the chief executive officer of Boston Scientific Corporation, which has about 59,000 employees.
Has BSX ever split its stock?
Yes. The most recent BSX stock split was a 2-for-1 split on Nov 6, 2003, one of 2 splits on record.